Experimental method for verifying bumetanib capable of improving cognitive impairment of schizophrenia

• Main Authors: LIU QING, CHEN YI, LI WENQIANG, YANG YONGFENG, SU XI, CHAI RUI, LYU LUXIAN, KANG NING
• Format: Patent
• Language: Chinese; English
• Published: 28.04.2023
• Subjects: AGRICULTURE; ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; FORESTRY; HUMAN NECESSITIES; HUNTING; HYGIENE; MEDICAL OR VETERINARY SCIENCE; NEW BREEDS OF ANIMALS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; TRAPPING

The invention provides an experimental method for verifying that bumetanib can improve cognitive impairment of schizophrenia. The experimental method is characterized by comprising the following steps: step 1, preparing rats of a schizophrenia model group and rats of a control group; 2, verifying that the schizophrenia model group rats have NKCC1/KCC2 expression imbalance through an immunoblotting experiment; and 3, verifying that the bumetanib can improve the cognitive impairment of the schizophrenia model group rats. Results of multiple experiments show that the schizophrenia model group rats have significant NKCC1/KCC2 imbalance, while the NKCC1/KCC2 system regulation drug bumetanib can significantly improve cognitive impairment of the schizophrenia model group rats, and the bumetanib has the advantages of short onset period and efficient and stable improvement effect, thereby proving the therapeutic value of bumetanib in schizophrenia cognitive impairment. 本发明提供一种验证布美他尼能改善精神分裂症认知损伤的实验方法，其特征在于包括以下步骤：步骤一：制备